Cargando…

Inhibition of effector B cells by ibrutinib in systemic sclerosis

OBJECTIVE: Systemic sclerosis (SSc) is a connective tissue disease with a significant morbidity and reduced survival of patients. Effective treatment and clinical control of the disease remain challenging. In particular, the development of pulmonary and cardiac fibrosis and pulmonary hypertension ar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Einhaus, Jakob, Pecher, Ann-Christin, Asteriti, Elisa, Schmid, Hannes, Secker, Kathy-Ann, Duerr-Stoerzer, Silke, Keppeler, Hildegard, Klein, Reinhild, Schneidawind, Corina, Henes, Joerg, Schneidawind, Dominik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7106617/ https://www.ncbi.nlm.nih.gov/pubmed/32228672 http://dx.doi.org/10.1186/s13075-020-02153-8

Ejemplares similares

Invariant natural killer T cells are functionally impaired in patients with systemic sclerosis
por: Pecher, Ann-Christin, et al.
Publicado: (2019)

Culture-Expanded Human Invariant Natural Killer T Cells Suppress T-Cell Alloreactivity and Eradicate Leukemia
por: Schmid, Hannes, et al.
Publicado: (2018)

Invariant NKT Cells From Donor Lymphocyte Infusions (DLI-iNKTs) Promote ex vivo Lysis of Leukemic Blasts in a CD1d-Dependent Manner
por: Jahnke, Simona, et al.
Publicado: (2019)

MAT2A as Key Regulator and Therapeutic Target in MLLr Leukemogenesis
por: Secker, Kathy-Ann, et al.
Publicado: (2020)

Human invariant natural killer T cells promote tolerance by preferential apoptosis induction of conventional dendritic cells
por: Schmid, Hannes, et al.
Publicado: (2021)

Only Hematopoietic Stem and Progenitor Cells from Cord Blood Are Susceptible to Malignant Transformation by MLL-AF4 Translocations
por: Secker, Kathy-Ann, et al.
Publicado: (2020)

Targeting MYC in combination with epigenetic regulators induces synergistic anti-leukemic effects in MLLr leukemia and simultaneously improves immunity
por: Fitzel, Rahel, et al.
Publicado: (2023)

Uncovering NOTCH1 as a Promising Target in the Treatment of MLL-Rearranged Leukemia
por: Fischer, Jacqueline, et al.
Publicado: (2023)

Optimal management of ANCA-associated vasculitis before and during pregnancy: current perspectives
por: Pecher, Ann-Christin, et al.
Publicado: (2022)

Editorial: Immune Tolerance Post Allogeneic Hematopoietic Cell Transplantation
por: Schneidawind, Dominik, et al.
Publicado: (2020)

Functionally Active Antibodies to the Angiotensin II Type 1-Receptor Measured by a Luminometric Bioassay Do Not Correlate With Clinical Manifestations in Systemic Sclerosis: A Comparison With Antibodies to Vascular Receptors and Topoisomerase I Detected by ELISA
por: Bankamp, Lukas, et al.
Publicado: (2021)

PB1803: SMAD1 IS A TUMOR SUPPRESSOR IN ACUTE MYELOID LEUKEMIA WITH MLL REARRANGEMENT
por: Dietsche, Lisa, et al.
Publicado: (2023)

Sexual dysfunction and depression in Behçet’s disease in comparison to healthy controls
por: Saur, Sebastian-Jonas, et al.
Publicado: (2021)

Immunological Adverse Events After Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis Patients
por: Strunz, Patrick-Pascal, et al.
Publicado: (2021)

Role of Lymphocyte Activation Gene-3 (Lag-3) in Conventional and Regulatory T Cell Function in Allogeneic Transplantation
por: Sega, Emanuela I., et al.
Publicado: (2014)

Freeze and Thaw of CD4(+)CD25(+)Foxp3(+) Regulatory T Cells Results in Loss of CD62L Expression and a Reduced Capacity to Protect against Graft-versus-Host Disease
por: Florek, Mareike, et al.
Publicado: (2015)

Haploidentical transplant with posttransplant cyclophosphamide vs matched related and unrelated donor transplant in acute myeloid leukemia and myelodysplastic neoplasm
por: Rieger, Max J., et al.
Publicado: (2023)

Macrophage-Mediated Antibody Dependent Effector Function in Aggressive B-Cell Lymphoma Treatment is Enhanced by Ibrutinib via Inhibition of JAK2
por: Barbarino, Verena, et al.
Publicado: (2020)

SETDB2 Links E2A-PBX1 to Cell-Cycle Dysregulation in Acute Leukemia through CDKN2C Repression
por: Lin, Chiou-Hong, et al.
Publicado: (2018)

Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status
por: Fehm, Tanja, et al.
Publicado: (2007)

Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia
por: Arthurs, Benjamin, et al.
Publicado: (2017)

Ibrutinib-induced cardiomyopathy
por: Kyi, Htay Htay, et al.
Publicado: (2019)

Extrahepatic metabolism of ibrutinib
por: Rood, Johannes J. M., et al.
Publicado: (2020)

Effectiveness and Safety of Ibrutinib for Chronic Lymphocytic Leukemia in Routine Clinical Practice: 3-Year Follow-up of the Belgian Ibrutinib Real-World Data (BiRD) Study
por: Janssens, Ann, et al.
Publicado: (2022)

Ibrutinib: Rebound effect in the form of respiratory deterioration following the discontinuation of ibrutinib: case report
Publicado: (2021)

A High-Throughput Clinical Laboratory Methodology for the Therapeutic Monitoring of Ibrutinib and Dihydrodiol Ibrutinib
por: Karvaly, Gellért Balázs, et al.
Publicado: (2022)

Ibrutinib for B cell malignancies
por: Novero, Aileen, et al.
Publicado: (2014)

Ibrutinib-Induced Skin Rash
por: Kirar, Sudhir, et al.
Publicado: (2021)

Ibrutinib: Pneumonitis: case report
Publicado: (2021)

Arrhythmia Patterns in Patients on Ibrutinib
por: Fazal, Muhammad, et al.
Publicado: (2022)

Human β-Defensin 2 Mediated Immune Modulation as Treatment for Experimental Colitis
por: Koeninger, Louis, et al.
Publicado: (2020)

Effects of common haplotypes of the ileal sodium dependent bile acid transporter gene on the development of sporadic and familial colorectal cancer: A case control study
por: Grünhage, Frank, et al.
Publicado: (2008)

1130. Low Risk of Pneumocystis jiroveci Pneumonia in Patients With Waldenstrom’s Macroglobulinemia on Ibrutinib
por: Kusztos, Amanda E, et al.
Publicado: (2018)

Profound Sinoatrial Arrest Associated with Ibrutinib
por: Mathur, Kanupriya, et al.
Publicado: (2017)

Ibrutinib‐induced severe liver injury
por: Nandikolla, Amara G., et al.
Publicado: (2017)

Electrocardiographic Changes Associated With Ibrutinib Exposure
por: Fradley, Michael G., et al.
Publicado: (2020)

Ibrutinib dose modifications in the management of CLL
por: Hardy-Abeloos, Camille, et al.
Publicado: (2020)

Invasive Aspergillosis in Patients Treated With Ibrutinib
por: Fürstenau, Moritz, et al.
Publicado: (2020)

Cystoid macular edema secondary to ibrutinib
por: Ben-Avi, Ravid, et al.
Publicado: (2022)

Death from diltiazem–ibrutinib interaction
por: Falconer, Nazanin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7o2akd48ttp34d31oq67a2lggm